Home Cart Sign in  
Chemical Structure| 52705-93-8 Chemical Structure| 52705-93-8

Structure of Ginsenoside Rd
CAS No.: 52705-93-8

Chemical Structure| 52705-93-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ginsenoside Rd is a protopanaxadiol which has diverse in vitro and in vivo effects, including cardioprotective, neuroprotective, and anti-inflammatory actions.

Synonyms: Gypenoside VIII; Panaxoside Rd; Sanchinoside Rd

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ginsenoside Rd

CAS No. :52705-93-8
Formula : C48H82O18
M.W : 947.15
SMILES Code : C[C@@]12[C@@]([H])([C@](C)([C@]3(CC2)[H])CC[C@@H](C3(C)C)O[C@@H]([C@@H]4O[C@@H]5O[C@@H]([C@H]([C@@H]([C@H]5O)O)O)CO)O[C@@H]([C@H]([C@@H]4O)O)CO)C[C@H]([C@]6([C@]1(CC[C@@H]6C(C)(O[C@@H]7O[C@@H]([C@H]([C@@H]([C@H]7O)O)O)CO)CC/C=C(C)\C)C)[H])O
Synonyms :
Gypenoside VIII; Panaxoside Rd; Sanchinoside Rd
MDL No. :MFCD00210508
InChI Key :RLDVZILFNVRJTL-IWFVLDDISA-N
Pubchem ID :11679800

Safety of Ginsenoside Rd

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Calcium Channel

In Vitro:

Cell Line
Concentration Treated Time Description References
Human skeletal myoblasts (HSkM) myotubes 100 nM 24 hours GRd ameliorates TNF-α-induced myotube atrophy PMC9745546
3T3-L1 adipocytes 20 μM 24 hours Ginsenoside Rd promoted omentin expression in adipocytes through the TBK1-AMPK signaling pathway, thereby improving adipocyte inflammation. PMC9860421
Human brain microvessel endothelial cells (HBMECs) 5, 15, 30 μM 12 hours To evaluate the protective effects of Ginsenoside Rd on OGD/R-induced injury in HBMECs. Results showed that Ginsenoside Rd significantly restored cell viability, attenuated OGD/R-induced BBB integrity damage, and suppressed NLRP3 inflammasome activation and pyroptosis. PMC9459060
Human Umbilical Vein Endothelial Cells (HUVECs) 1-50 μmol/L 24 hours To evaluate the effect of Ginsenoside Rd on migration and tube formation capacity of HUVECs. Results showed that Rd at 1-50 μmol/L significantly inhibited the migration and tube formation of HUVECs, especially under hypoxia conditions. PMC7564034
Mouse C2C12 myotubes 10-1000 nM 24 hours GRd significantly increased the diameter of C2C12 myotubes in a dose-dependent manner PMC9745546
PC12 cells 25, 50, 100 μmol/L 6 hours Rd significantly increased the expression of VEGF and BDNF, dose-dependently increased the phosphorylation of Akt and ERK, and significantly decreased PC12 cell apoptosis, which were blocked by co-application of LY294002. PMC4387301
Primary rat retinal vascular endothelial cells (RVECs) 30 µM Ginsenoside Rd reduces ROS production by enhancing AMPK-SIRT1 interaction, reverses endothelial mitochondrial intrinsic apoptosis, and ameliorates high glucose-induced endothelial barrier dysfunction. PMC11909904

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Balb/c nude mice LoVo colorectal cancer xenograft model Intraperitoneal injection 5 mg/kg/day Once daily for 15 days To evaluate the effect of Ginsenoside Rd on tumor angiogenesis. Results showed that Rd significantly suppressed neovascularization in tumors, normalized the structure of tumor vessels, and improved the anti-tumor effect of 5-fluorouracil (5FU) in xenograft mice. PMC7564034
C57BL/6J mice Transverse aortic constriction (TAC)-induced heart failure model Intragastric administration 5 mg/kg, 10 mg/kg, 20 mg/kg Once daily for 4 weeks Ginsenoside Rd improved cardiac function and inhibited cardiac pathological changes in TAC-induced HF mice by promoting omentin secretion from adipocytes. PMC9860421
Mice Aging model and tumor model (LLC1 or CT26) Oral 10 mg/kg body weight Aging model: daily for 5 weeks; Tumor model: daily for 16 days GRd ameliorates aging- and tumor-induced muscle atrophy, evidenced by significant increases in grip strength, hanging time, muscle mass, and muscle tissue cross-sectional area PMC9745546
SD rats Transient middle cerebral artery occlusion (MCAO) model Intraperitoneal injection 1, 2.5, 5 mg/kg/d Once daily for 3 days Rd dose-dependently decreased the infarct size and neurological scores, significantly increased Akt phosphorylation, and markedly increased the number of BrdU/DCX and Nestin/GFAP double-positive cells, which were partially blocked by co-administration of LY294002. PMC4387301
C57BL/6 male mice STZ-induced diabetic retinopathy model Topical ocular administration 0.5% or 1% eye drops (5 µl daily) Once daily for three months Ginsenoside Rd significantly alleviated retinal thickness reduction, disorganized architecture, and neuronal cell loss in diabetic mice, decreased retinal MDA content, reduced acellular capillary formation, improved vascular abnormalities and tortuosity, inhibited Evans blue dye extravasation, and restored junctional proteins (VE-cadherin, ZO-1, Occludin, Cx43) expression. PMC11909904
Sprague-Dawley rats Middle cerebral artery occlusion (MCAO) model Intraperitoneal injection 30 mg/kg 1 hour before surgery, 10 mg/kg/d after surgery Single dose 1 hour before surgery, daily dose after surgery until sacrifice GSRd improved survival rate and neurological scores, reduced DNA damage and apoptosis, up-regulated NEIL1 and NEIL3 expressions PMC4989428

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.06mL

0.21mL

0.11mL

5.28mL

1.06mL

0.53mL

10.56mL

2.11mL

1.06mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories